Alembic Pharmaceuticals Limited has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Venetoclax Tablets, available in 10 mg, 50 mg, and 100 mg strengths. This approval marks a significant step for the company, allowing it to enter the US market with a vital cancer treatment. The drug is indicated for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), as well as newly diagnosed acute myeloid leukemia (AML) in specific adult patient groups.
USFDA Final Approval Secured
Alembic Pharmaceuticals Limited announced today that it has received the final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA). The approval pertains to Venetoclax Tablets in strengths of 10 mg, 50 mg, and 100 mg.
Therapeutic Indications and Market Potential
The approved Venetoclax Tablets are therapeutically equivalent to Venclexta Tablets by AbbVie Inc. They are indicated for the treatment of adult patients diagnosed with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Furthermore, the tablets are also approved for use in combination with other therapies for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults aged 75 years or older, or those with comorbidities that prevent intensive induction chemotherapy.
Generic Drug Exclusivity
Alembic Pharmaceuticals was among the first ANDA applicants to submit a substantially complete ANDA with a paragraph IV certification for Venetoclax Tablets. This strategic filing positions Alembic to be eligible for 180 days of generic drug exclusivity in the US market. The market for Venetoclax tablets was estimated at US $1,584 million in the United States for the twelve months ending June 2026, according to IQVIA data.
Company Milestones and Outlook
With this USFDA approval, Alembic Pharmaceuticals’ cumulative total of ANDA approvals from the USFDA now stands at 248, comprising 228 final approvals and 20 tentative approvals. This achievement underscores Alembic’s robust research and development capabilities and its commitment to expanding access to critical medications globally.
Source: BSE
